| Not Yet Recruiting | Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine NCT07418372 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Recruiting | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid NCT06947499 | LG Chem | Phase 2 / Phase 3 |
| Recruiting | 10-year Follow-up After a Single Dose Acellular Pertussis Vaccination NCT06803524 | Mahidol University | Phase 4 |
| Active Not Recruiting | A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) NCT06708286 | CanSino Biologics Inc. | Phase 2 / Phase 3 |
| Not Yet Recruiting | Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healt NCT06618196 | LG Chem | Phase 2 |
| Recruiting | Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants NCT06605755 | Jiangsu Province Centers for Disease Control and Prevention | N/A |
| Recruiting | Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine NCT06184542 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1 |
| Recruiting | Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control NCT06286007 | Hospital Clinico Universitario de Santiago | — |
| Active Not Recruiting | A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) NCT06056050 | CanSino Biologics Inc. | Phase 1 |
| Unknown | Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy NCT06114160 | Université de Reims Champagne-Ardenne | — |
| Completed | Maternal Determinants of Infant Immunity to Pertussis NCT05856396 | Centre Hospitalier Universitaire Saint Pierre | Phase 4 |
| Unknown | A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults NCT05952596 | LG Chem | Phase 1 |
| Unknown | Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Prima NCT05457946 | LG Chem | Phase 2 / Phase 3 |
| Withdrawn | Pathogenic Bordetella Rapid Detection NCT04535505 | Children's Hospital of Fudan University | — |
| Unknown | Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-deto NCT05193734 | University Hospital, Geneva | Phase 2 / Phase 3 |
| Completed | Establishing a Controlled Human Infection Model of Bordetella Pertussis NCT05136599 | Dalhousie University | Phase 1 |
| Terminated | Pertussis Acellular Vaccine Adjuvanted With TQL1055 NCT04793620 | Adjuvance Technologies, Inc. | Phase 1 |
| Unknown | Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan NCT04779853 | Scientific and practical center of sanitary and epidemiological expertise and monitoring | — |
| Unknown | A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in Shenzhen NCT04694963 | Shenzhen People's Hospital | — |
| Unknown | A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen NCT04694430 | Shenzhen People's Hospital | — |
| Unknown | Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays NCT04023929 | St George's, University of London | — |
| Completed | Maternal Pertussis Wholecell Responses NCT04589312 | St George's, University of London | Phase 2 |
| Completed | 5-year Follow-up After a Single Dose Acellular Pertussis Vaccination NCT04529720 | Mahidol University | — |
| Completed | Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Ads NCT04099303 | CanSino Biologics Inc. | Phase 1 |
| Unknown | To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Child NCT04618640 | Boryung Biopharma Co., Ltd. | Phase 3 |
| Unknown | Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants NCT04073459 | LG Chem | Phase 2 |
| Unknown | A Phase IV Study to Assess the Safety of EupentaTM Inj NCT04056728 | LG Chem | Phase 4 |
| Completed | Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults NCT03942406 | ILiAD Biotechnologies | Phase 2 |
| Completed | Pertussis Vaccination in Pregnant Women NCT03909126 | St. Justine's Hospital | Phase 4 |
| Unknown | Optimising the Timing of Whooping Cough Immunisation in MUMs NCT03908164 | St George's, University of London | Phase 4 |
| Completed | Confirmatory Study of BK1310 in Healthy Infants NCT03891758 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants NCT03589768 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Gambia Pertussis Study (GaPs) NCT03606096 | London School of Hygiene and Tropical Medicine | Phase 4 |
| Completed | Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults NCT03541499 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System NCT03950986 | Atlanta VA Medical Center | N/A |
| Unknown | Maternal Antibody in Milk After Vaccination NCT03982732 | St George's, University of London | — |
| Completed | Evaluation of an Infant Immunization Encouragement Program in Nigeria NCT03870061 | GiveWell | N/A |
| Completed | 3-year Follow-up After a Single Dose Acellular Pertussis Vaccination NCT04102137 | Mahidol University | — |
| Completed | Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of NCT03498300 | Mahidol University | EARLY_Phase 1 |
| Completed | A Study Exploring Whooping Cough Protection in Children and Adults NCT03697798 | University of Oxford | Phase 4 |
| Completed | The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine NCT03931239 | Vabiotech | N/A |
| Unknown | Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan NCT03341195 | Aga Khan University | N/A |
| Completed | Adacel® Booster Vaccination for CMI Assay Development NCT04543669 | Dalhousie University | Phase 4 |
| Completed | The Feasibility of Pertussis Immunization in a Canadian Emergency Department NCT03304275 | University of Prince Edward Island | N/A |
| Completed | A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults NCT03208101 | LG Chem | Phase 1 |
| Completed | 2-year Follow-up After a Single Dose Acellular Pertussis Vaccination NCT04113655 | Mahidol University | — |
| Completed | Observational Study Describing the Immune Profile Induced By Pertussis Vaccines NCT03147898 | Sanofi | — |
| Terminated | CD8 Reactivity to Microorganisms in Blood and Breast Milk NCT03084614 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Pertussis Immunization During Pregnancy & HIV Infection NCT03519373 | Centre Hospitalier Universitaire Saint Pierre | — |
| Completed | The PertADO Geneva Trial NCT02946190 | Siegrist Claire-Anne | Phase 2 |
| Completed | A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a NCT02858440 | GlaxoSmithKline | Phase 3 |
| Completed | DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infect NCT02817451 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Maternal Tdap Immunization in Guatemala NCT02301702 | Emory University | Phase 2 |
| Completed | Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Prev NCT02759354 | MCM Vaccines B.V. | Phase 3 |
| Completed | Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda NCT04177485 | Centers for Disease Control and Prevention | N/A |
| Completed | Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjec NCT02587520 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine NCT02453048 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 1 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 NCT02428491 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1) NCT02382913 | Novartis | Phase 1 |
| Completed | Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand NCT02408926 | Universiteit Antwerpen | Phase 4 |
| Unknown | Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Week NCT02257645 | LG Life Sciences | — |
| Completed | Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS NCT02458183 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunis NCT01890447 | GlaxoSmithKline | — |
| Unknown | Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants NCT02511327 | Universiteit Antwerpen | — |
| Completed | DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Ja NCT02274285 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | TDAP Safety in Pregnant Women NCT02209623 | Vanderbilt University | — |
| Completed | A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary NCT02014519 | GlaxoSmithKline | N/A |
| Completed | Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents NCT02118961 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Boostrix® Pregnancy Registry NCT02096276 | GlaxoSmithKline | — |
| Completed | DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed NCT02094833 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years NCT02089347 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants NCT02477995 | Jiangsu Province Centers for Disease Control and Prevention | Phase 3 |
| Completed | How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice NCT01979588 | Endeavor Health | N/A |
| Completed | Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vac NCT01993173 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve NCT01878435 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject NCT01917357 | Crucell Holland BV | Phase 3 |
| Completed | Pertussis and Meningitis C Concomitant Vaccination in Adolescents NCT02526394 | Public Health England | Phase 4 |
| Completed | Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China NCT01933776 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Protecting Pregnant Women From Infectious Diseases NCT01761799 | Emory University | N/A |
| Completed | Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals NCT01706224 | GlaxoSmithKline | — |
| Completed | Tdap Vaccine in Post-Partum Women NCT01711645 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in A NCT01689324 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age NCT01659996 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Pertussis Infection in Adolescents and Adults With Prolonged Cough NCT01597687 | GlaxoSmithKline | N/A |
| Completed | Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents NCT01629589 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vacci NCT01529645 | Novartis Vaccines | Phase 1 |
| Completed | Pertussis (Tdap) Vaccination in Pregnancy NCT01698346 | Universiteit Antwerpen | Phase 4 |
| Completed | Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 NCT01470287 | Novartis Vaccines | Phase 3 |
| Completed | Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China NCT01491087 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose NCT01439165 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Regulatory Post-Marketing Surveillance Study for TETRAXIM™ NCT01437423 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vac NCT01357720 | Crucell Holland BV | Phase 4 |
| Completed | Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age NCT01346293 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Testing the Use of Prompts to Increase Adolescent Immunization Rates NCT01984125 | University of California, Los Angeles | N/A |
| Completed | Study of Adacel® Vaccine Administered to Persons 10 Years of Age NCT01311557 | Sanofi | Phase 4 |
| Completed | Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEV NCT01287949 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, NCT01249183 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. NCT01214889 | Sanofi | Phase 3 |
| Completed | First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine NCT01188512 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 1 |
| Completed | Tdap Vaccination for Infant Caregivers NCT01233401 | Yale University | — |
| Completed | Post Marketing Surveillance for ADACEL™ in South Korea NCT01137435 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by NCT01362517 | Crucell Holland BV | Phase 3 |
| Completed | Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines NCT01129362 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy NCT01062477 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age NCT01031303 | Sanofi | Phase 4 |
| Withdrawn | A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly NCT01003431 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Assess the Safety of Adacel® Vaccine NCT01040052 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster NCT00870350 | Swedish Institute for Infectious Disease Control | Phase 4 |
| Completed | Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease NCT00855855 | Sanofi Pasteur, a Sanofi Company | — |
| Unknown | Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine NCT00877357 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Pertussis Vaccine in Healthy Pregnant Women NCT00707148 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Immunogenicity and Safety of Adacel Polio Vaccine NCT00797511 | Sanofi | Phase 3 |
| Completed | Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting NCT00828555 | Duke University | — |
| Completed | Database Surveillance Safety Study of PENTACEL® Vaccine NCT00804284 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose NCT00712959 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants NCT00831753 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine NCT00674908 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine NCT00617812 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infan NCT00654901 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish NCT00619502 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino NCT00514709 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix NCT00534833 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents NCT00518180 | Novartis Vaccines | Phase 3 |
| Completed | Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure NCT00469274 | Vanderbilt University | N/A |
| Completed | Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine NCT00514059 | Norwegian Institute of Public Health | Phase 4 |
| Completed | Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age NCT00467519 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older NCT00457249 | Sanofi | Phase 4 |
| Unknown | Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease NCT00932269 | Swedish Institute for Infectious Disease Control | — |
| Completed | Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months NCT00453570 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) NCT00432042 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants NCT00404651 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL NCT00355121 | Sanofi | Phase 2 |
| Completed | Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai NCT00401531 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Pr NCT00362427 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paedia NCT00362336 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine NCT00347958 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio NCT00343889 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months NCT00315055 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and NCT00313911 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and To NCT00343421 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients NCT00336115 | Queen Elizabeth II Health Sciences Centre | Phase 4 |
| Completed | Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy I NCT00348881 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and NCT00319553 | Sanofi | Phase 4 |
| Completed | Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV NCT00319852 | Sanofi | Phase 3 |
| Completed | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine NCT00304265 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule NCT00287092 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentine NCT00303316 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim™ in an Indian Population NCT00259337 | Sanofi | Phase 3 |
| Completed | Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine NCT00258882 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunology of Non-specific Effects of Vaccine NCT00168545 | Bandim Health Project | Phase 4 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand NCT00255021 | Sanofi | Phase 4 |
| Completed | Pentavalent DTaP-Hep B-IPV NCT00133445 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety and Immune Response of Different Pediatric Combination Vaccines. NCT00255047 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan NCT00258908 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim in South African Infants NCT00254969 | Sanofi | Phase 3 |
| Completed | Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine NCT00777257 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or NCT00258895 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 1 NCT00158808 | GlaxoSmithKline | Phase 2 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinea NCT00831311 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age NCT00524732 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ NCT00802867 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines NCT00254917 | Sanofi | Phase 4 |
| Completed | Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ NCT00772928 | Sanofi | Phase 3 |
| Completed | Retrospective Survey of Safety of Fourth Dose Pentacel® in Children NCT00772369 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of NCT00291967 | GlaxoSmithKline | Phase 2 |
| Completed | Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) NCT00092469 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separatel NCT01457508 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Pol NCT02040636 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly NCT01457495 | GlaxoSmithKline | Phase 2 |
| Completed | Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults NCT01267058 | GlaxoSmithKline | Phase 3 |
| Completed | Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection NCT00004422 | IWK Health Centre | Phase 3 |
| Completed | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines NCT00004800 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines NCT00004799 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Pilot Study Freeze and Transport Immune Cells NCT00138268 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs NCT00013871 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |